abiraterone accord
accord healthcare s.l.u. - octan abirateronu - nowotwory stercza - terapia endokrynologiczna - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
abiraterone krka
krka, d.d., novo mesto - octan abirateronu - nowotwory stercza - terapia endokrynologiczna - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
abiraterone mylan
mylan ireland limited - octan abirateronu - nowotwory stercza - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
zytiga
janssen-cilag international n.v. - octan abirateronu - nowotwory stercza - terapia endokrynologiczna - zytiga podana z prednizonu lub prednizolonu w leczeniu przerzutowego kastracji odporne na raka gruczołu krokowego u mężczyzn przebiega bezobjawowo lub słabo objawy po awarii androgenów-депривационной terapii w których chemioterapia nie klinicznie indicatedthe traktowania przerzutowy odpornego odporny rak prostaty u dorosłego mężczyzny, którego choroba postępowała po chemioterapii na podstawie docetaksela tryb.
abiraterone fresenius kabi 500 mg tabletki powlekane
fresenius kabi polska sp. z o.o. - abirateronum - tabletki powlekane - 500 mg
abirateron teva 500 mg tabletki powlekane
teva b.v. - abirateronu octan - tabletki powlekane - 500 mg
abirateron sun 500 mg tabletki powlekane
sun pharmaceutical industries europe b.v. - abirateronu octan - tabletki powlekane - 500 mg
octanate 50 j.m./ml proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań i infuzji
octapharma (ip) sprl - factor viii coagulationis humanus - proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań i infuzji - 50 j.m./ml
octanate 100 j.m./ml proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań
octapharma (ip) sprl - factor viii coagulationis humanus - proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań - 100 j.m./ml
octanate lv 100 j.m./ml proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań
octapharma (ip) sprl - factor viii coagulationis humanus - proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań - 100 j.m./ml